Gamma Biosciences, a life sciences platform established by KKR to address the advanced therapy bioprocessing market, today announced that it has entered into an agreement with Merck KGaA, Darmstadt, Germany (XTRA:MRK), a leading science and technology company, whereby Merck KGaA, Darmstadt, Germany, will acquire Gamma operating company Mirus Bio for $600 million in cash.
Mirus Bio has been named a Top Workplace 2024 by Wisconsin State Journal Top Workplaces. This award is based solely on employee feedback collected from a survey administered by an external organization.
Mirus Bio Receives ISO 13485:2016 Certification Completion of this comprehensive certification process underscores the quality of the processes used to support the company’s GMP product
Delivers 2-4x increase in AAV titers across many serotypes, cell lines, growth media, and transfection reagents Significantly reduces production costs and doubles the doses that
The two companies will collaborate to combine industry-leading technologies and tackle the non-viral delivery of highly complex genome engineering materials to help create human cellular
Menlo Park, CA and Madison, WI (Mar 22, 2022) ‒ Gamma Biosciences, a global life sciences company serving the advanced therapy market, today announced an initiative
Madison, Wis. (Feb 24, 2022) ‒ Mirus Bio, a leading provider of delivery solutions within Gamma Biosciences, today launched TransIT-VirusGEN® SELECT Transfection Kits for large-scale viral vector
Menlo Park CA and Madison, WI (December 14, 2021) – Gamma Biosciences, a global life sciences company serving the academic and advanced therapy market, today announced the
Madison, Wis. (August 5, 2021) – Mirus Bio, an innovator in transfection technologies, today announces the launch of the TransIT® VirusGEN® GMP product line. This expansion
Madison, WI and Menlo Park, CA (May 18, 2021) – Mirus Bio, an innovator in transfection technologies announced that they are entering into a partnership with
Madison, Wis. (July 25, 2019) ‒ The TransIT-VirusGEN® SELECT Transfection Reagent is developed for large-scale virus production for preclinical and early phase clinical trials and is identical
Madison, Wis. (May 1, 2019) ‒ Researchers now have an opportunity to achieve higher protein yields from transient transfection of suspension CHO cells. The CHOgro® High